Alyeska Investment Group
LRMR icon

Alyeska Investment Group’s Larimar Therapeutics LRMR Stock Holding History

Alyeska Investment Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Hold
617,211
– – ﹤0.01% 575
2026
Q1 		$2.78M Sell
617,211
-310,610
-33% -$1.24M 0.01% 531
2025
Q4 		$3.53M Sell
927,821
-959,348
-51% -$3.73M 0.01% 485
2025
Q3 		$6.1M Sell
1,887,169
-188,713
-9% -$708K 0.02% 434
2025
Q2 		$6M Buy
2,075,882
+633,409
+44% +$1.47M 0.02% 400
2025
Q1 		$3.1M Buy
1,442,473
+458,396
+47% +$1.45M 0.01% 394
2024
Q4 		$3.81M Buy
984,077
+273,920
+39% +$1.81M 0.01% 416
2024
Q3 		$4.65M Sell
710,157
-111,530
-14% -$896K 0.02% 363
2024
Q2 		$5.96M Buy
821,687
+271,660
+49% +$2.08M 0.03% 315
2024
Q1 		$4.17M Buy
+550,027
New +$4.29M 0.03% 341
2022
Q4 		– Sell
-133,073
Closed -$426K – 469
2022
Q3 		$426K Buy
+133,073
New +$333K 0.01% 363
2018
Q3 		– Sell
-20,833
Closed -$2.56M – 469
2018
Q2 		$2.56M Buy
+20,833
New +$1.77M 0.02% 332
2016
Q3 		– Sell
-13,166
Closed -$946K – 502
2016
Q2 		$946K Buy
13,166
+267
+2% +$21.1K 0.01% 388
2016
Q1 		$1.03M Sell
12,899
-1,277
-9% -$101K 0.01% 354
2015
Q4 		$1.07M Buy
+14,176
New +$2.28M 0.01% 338
2015
Q1 		– Sell
-10,285
Closed -$3.81M – 547
2014
Q4 		$3.81M Sell
10,285
-294
-3% -$75.8K 0.06% 292
2014
Q3 		$2.5M Sell
10,579
-5,195
-33% -$1.18M 0.05% 274
2014
Q2 		$3.74M Buy
+15,774
New +$3.75M 0.08% 258

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Alyeska Investment Group's LRMR Position: Q2 2026 in Review

Alyeska Investment Group held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 617,211 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Alyeska Investment Group first reported a position in LRMR in Q2 2014 and has held it in 18 quarters since. The position peaked at $6.1M in Q3 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Alyeska Investment Group held 617,211 shares of Larimar Therapeutics worth $1.88M as of Q2 2026.
  • Alyeska Investment Group left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #575 holding.
  • Alyeska Investment Group first reported a position in Larimar Therapeutics in Q2 2014 and has held it in 18 quarters since.
  • Alyeska Investment Group's Larimar Therapeutics position peaked at $6.1M in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.